论文部分内容阅读
[目的]结合临床实践经验,探讨大剂量沐舒坦治疗小儿急性肺损伤的临床疗效。[方法]采用对照研究法,将患儿随机分为3组,分别为对照组(44例)、常规剂量组(44例)和大剂量组(44例),3组采用不同的治疗方法,通过对比分析,探讨大剂量沐舒坦治疗小儿急性肺损伤的临床疗效。采用Microsoft Excel建立数据库,运用SPSS13.0统计软件进行统计分析。所有计量资料用(均数±标准差)表示,采用t检验以及χ2检验,取P﹤0.05为差异有统计学意义。[结果]治疗前,3组间PaO2及PaO2/FiO2差异无统计学意义。治疗后PaO2及PaO2/FiO2较治疗前明显好转,治疗3d后,大剂量组PaO2及PaO2/FiO2明显高于对照组和常规剂量组,差异有统计学意义(P﹤0.05)。对照组、常规剂量组和大剂量组经治疗进展到ARDS者分别有10、8、2例,组间比较有差异有统计学意义,其中分别有6、5和1例死亡,死亡率各组间差异无统计学意义。剔除ARDS病例后,大剂量组PaO2/FiO2恢复到300mmHg以上时间明显短于常规剂量组和对照组,差异有统计学意义(P﹤0.05),而常规剂量组和对照组间对方差异无统计学意义(P﹥0.05)。[结论]沐舒坦对小儿ALI患者肺功能有明显的保护作用,应用大剂量沐舒坦对小儿ALI的预防、治疗和转归具有良好的疗效,值得临床推广应用。
[Objective] To explore the clinical efficacy of high-dose ambroxol in the treatment of children with acute lung injury. [Methods] The children were randomly divided into three groups: control group (44 cases), conventional dosage group (44 cases) and high dosage group (44 cases). The three groups were treated with different methods, Through comparative analysis, to explore the clinical efficacy of high-dose ambroxol treatment of children with acute lung injury. Using Microsoft Excel to establish a database, using SPSS13.0 statistical software for statistical analysis. All measurement data (mean ± standard deviation) said, using t test and χ2 test, take P <0.05 for the difference was statistically significant. [Results] There was no significant difference in PaO2 and PaO2 / FiO2 between the three groups before treatment. After treatment, PaO2 and PaO2 / FiO2 were significantly improved compared with those before treatment. PaO2 and PaO2 / FiO2 in high-dose group were significantly higher than those in control group and conventional dose group after 3 days of treatment, with significant difference (P <0.05). The control group, conventional dose group and high dose group were treated to ARDS were 10,8,2 cases, there were significant differences between the groups were statistically significant, respectively, there were 6,5 and 1 deaths, the mortality of each group There was no significant difference between the two groups. Excluding ARDS cases, the PaO2 / FiO2 recovery time to 300mmHg in the high-dose group was significantly shorter than that in the conventional dose group and the control group (P <0.05), but there was no significant difference between the conventional dose group and the control group Significance (P> 0.05). [Conclusion] Mucosolvan has a significant protective effect on pulmonary function in children with ALI. The high dose of ambroxol has a good curative effect on the prevention, treatment and prognosis of children with ALI, which is worthy of clinical application.